Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature communications Jg. 14; H. 1; S. 1273 - 10
Hauptverfasser:	Grewal, Ramandip, Nguyen, Lena, Buchan, Sarah A., Wilson, Sarah E., Nasreen, Sharifa, Austin, Peter C., Brown, Kevin A., Fell, Deshayne B., Gubbay, Jonathan B., Schwartz, Kevin L., Tadrous, Mina, Wilson, Kumanan, Kwong, Jeffrey C.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 07.03.2023 Nature Publishing Group Nature Portfolio
Schlagworte:	631/326/590 631/326/596/4130 692/700/459/1748 692/700/478/174 Adult Adults Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Effectiveness Humanities and Social Sciences Humans Immunization Immunization, Secondary mRNA multidisciplinary Ontario - epidemiology RNA, Messenger SARS-CoV-2 Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Vaccine efficacy Vaccines Ontario Ontario Canada Canada
ISSN:	2041-1723, 2041-1723
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91–98% 7–59 days after a third dose, waned to 76–87% after ≥240 days, was restored to 92–97% 7–59 days after a fourth dose, and waned to 86–89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance. This study investigates the protection provided by mRNA COVID-19 vaccine booster doses against Omicron-associated severe disease in adults aged 50 and older. The authors use data from Ontario, Canada, and find that booster doses provide strong protection but that it declined during the period of BA.4/BA.5 predominance.
AbstractList	We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91–98% 7–59 days after a third dose, waned to 76–87% after ≥240 days, was restored to 92–97% 7–59 days after a fourth dose, and waned to 86–89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance. This study investigates the protection provided by mRNA COVID-19 vaccine booster doses against Omicron-associated severe disease in adults aged 50 and older. The authors use data from Ontario, Canada, and find that booster doses provide strong protection but that it declined during the period of BA.4/BA.5 predominance. We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91–98% 7–59 days after a third dose, waned to 76–87% after ≥240 days, was restored to 92–97% 7–59 days after a fourth dose, and waned to 86–89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance. This study investigates the protection provided by mRNA COVID-19 vaccine booster doses against Omicron-associated severe disease in adults aged 50 and older. The authors use data from Ontario, Canada, and find that booster doses provide strong protection but that it declined during the period of BA.4/BA.5 predominance. We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91-98% 7-59 days after a third dose, waned to 76-87% after ≥240 days, was restored to 92-97% 7-59 days after a fourth dose, and waned to 86-89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance. Abstract We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91–98% 7–59 days after a third dose, waned to 76–87% after ≥240 days, was restored to 92–97% 7–59 days after a fourth dose, and waned to 86–89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance. We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91-98% 7-59 days after a third dose, waned to 76-87% after ≥240 days, was restored to 92-97% 7-59 days after a fourth dose, and waned to 86-89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance.We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario, Canada. We used a test-negative design to estimate vaccine effectiveness (VE) against hospitalization or death among SARS-CoV-2-tested adults aged ≥50 years from January 2 to October 1, 2022, stratified by age and time since vaccination. We also compared VE during BA.1/BA.2 and BA.4/BA.5 sublineage predominance. We included 11,160 cases and 62,880 tests for test-negative controls. Depending on the age group, compared to unvaccinated adults, VE was 91-98% 7-59 days after a third dose, waned to 76-87% after ≥240 days, was restored to 92-97% 7-59 days after a fourth dose, and waned to 86-89% after ≥120 days. VE was lower and declined faster during BA.4/BA.5 versus BA.1/BA.2 predominance, particularly after ≥120 days. Here we show that booster doses of monovalent mRNA COVID-19 vaccines restored strong protection against severe outcomes for at least 3 months after vaccination. Across the entire study period, protection declined slightly over time, but waned more during BA.4/BA.5 predominance.
ArticleNumber	1273
Author	Tadrous, Mina Austin, Peter C. Kwong, Jeffrey C. Gubbay, Jonathan B. Schwartz, Kevin L. Wilson, Sarah E. Buchan, Sarah A. Nguyen, Lena Fell, Deshayne B. Grewal, Ramandip Nasreen, Sharifa Wilson, Kumanan Brown, Kevin A.
Author_xml	– sequence: 1 givenname: Ramandip orcidid: 0000-0002-1922-2442 surname: Grewal fullname: Grewal, Ramandip organization: Public Health Ontario – sequence: 2 givenname: Lena surname: Nguyen fullname: Nguyen, Lena organization: ICES – sequence: 3 givenname: Sarah A. surname: Buchan fullname: Buchan, Sarah A. organization: Public Health Ontario, ICES, Dalla Lana School of Public Health, University of Toronto, Centre for Vaccine Preventable Diseases, University of Toronto – sequence: 4 givenname: Sarah E. surname: Wilson fullname: Wilson, Sarah E. organization: Public Health Ontario, ICES, Dalla Lana School of Public Health, University of Toronto, Centre for Vaccine Preventable Diseases, University of Toronto – sequence: 5 givenname: Sharifa orcidid: 0000-0002-9793-113X surname: Nasreen fullname: Nasreen, Sharifa organization: ICES, Dalla Lana School of Public Health, University of Toronto – sequence: 6 givenname: Peter C. surname: Austin fullname: Austin, Peter C. organization: ICES, Institute of Health Policy, Management and Evaluation, University of Toronto – sequence: 7 givenname: Kevin A. surname: Brown fullname: Brown, Kevin A. organization: Public Health Ontario, ICES, Dalla Lana School of Public Health, University of Toronto – sequence: 8 givenname: Deshayne B. orcidid: 0000-0002-5548-3228 surname: Fell fullname: Fell, Deshayne B. organization: ICES, School of Epidemiology and Public Health, University of Ottawa, Children’s Hospital of Eastern Ontario Research Institute – sequence: 9 givenname: Jonathan B. surname: Gubbay fullname: Gubbay, Jonathan B. organization: Public Health Ontario, Department of Laboratory Medicine and Pathobiology, University of Toronto – sequence: 10 givenname: Kevin L. orcidid: 0000-0002-3666-7005 surname: Schwartz fullname: Schwartz, Kevin L. organization: Public Health Ontario, ICES, Dalla Lana School of Public Health, University of Toronto – sequence: 11 givenname: Mina surname: Tadrous fullname: Tadrous, Mina organization: ICES, Women’s College Hospital, Leslie Dan Faculty of Pharmacy, University of Toronto – sequence: 12 givenname: Kumanan surname: Wilson fullname: Wilson, Kumanan organization: Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Bruyere Research Institute – sequence: 13 givenname: Jeffrey C. orcidid: 0000-0002-7820-2046 surname: Kwong fullname: Kwong, Jeffrey C. email: jeff.kwong@utoronto.ca organization: Public Health Ontario, ICES, Dalla Lana School of Public Health, University of Toronto, Centre for Vaccine Preventable Diseases, University of Toronto, Department of Family and Community Medicine, University of Toronto, University Health Network
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36882416$$D View this record in MEDLINE/PubMed
BookMark	eNp9UltvFCEYJabGXuwf8MFM4osvo9wGmBeTZm11k8ZNTPWVMMzHymYGKsxu4r-X3am17UMJCR9wzuEA5xQdhRgAoTcEfyCYqY-ZEy5kjSmrmWiEqMkLdEIxJzWRlB09qI_Rec4bXBprieL8FTpmQinKiThBN5fOgZ38DgLkXEVXjd-_XVSL1c_l55q01c5Y6wNUXYx5glT1MUOuzNr4kKdqNXqbYqgy7CBBFbeTjSPk1-ilM0OG87vxDP24urxZfK2vV1-Wi4vr2gosploYzq2i1DWkzDtLRamgY0K0pctGAAEFjoKRDesVY9hA6wT0UhknO8nO0HLW7aPZ6NvkR5P-6Gi8PizEtNYmTd4OoLGkwlpioeeGt9x2tldSUuUIw9CpvdanWet2243QWwhTMsMj0cc7wf_S67jTbdviRrAi8P5OIMXfW8iTHn22MAwmQNxmTaXiihUkLdB3T6CbuE2hPNUBRSiReO_o7UNH91b-fV4B0BlQ_iDnBO4eQrDeh0TPIdElJPoQEk0KST0hWT-Zycf9rfzwPJXN1FzOCWtI_20_w_oLLajPRA
CitedBy_id	crossref_primary_10_1007_s15010_025_02586_w crossref_primary_10_1016_j_vaccine_2023_10_035 crossref_primary_10_3389_fpubh_2024_1402527 crossref_primary_10_1016_j_vaccine_2024_05_003 crossref_primary_10_1109_ACCESS_2023_3298557 crossref_primary_10_1128_spectrum_05256_22 crossref_primary_10_1148_radiol_231928 crossref_primary_10_1016_j_vaccine_2024_05_041 crossref_primary_10_13105_wjma_v11_i5_167 crossref_primary_10_3389_fimmu_2023_1303058 crossref_primary_10_1177_00033197241251905 crossref_primary_10_3390_vaccines11081325 crossref_primary_10_3390_biom15040541 crossref_primary_10_1016_j_ebiom_2025_105662 crossref_primary_10_3389_fimmu_2025_1603612 crossref_primary_10_1093_cid_ciad716 crossref_primary_10_3390_vaccines11101624 crossref_primary_10_3390_vaccines13030244 crossref_primary_10_1093_ofid_ofaf185 crossref_primary_10_1093_ofid_ofad187 crossref_primary_10_1002_jmv_70487 crossref_primary_10_1093_aje_kwae125 crossref_primary_10_1093_cid_ciae182 crossref_primary_10_1080_14760584_2024_2310807 crossref_primary_10_1186_s12961_023_01036_z crossref_primary_10_1080_14760584_2023_2265460 crossref_primary_10_1038_s41598_025_91246_y crossref_primary_10_1093_infdis_jiaf054 crossref_primary_10_1016_j_hlpt_2023_100801 crossref_primary_10_1080_14760584_2023_2290931
Cites_doi	10.1136/bmj-2022-071502 10.1056/NEJMc2213907 10.1056/NEJMoa2201688 10.1056/NEJMoa2201570 10.1136/bmj-2022-071113 10.1056/NEJMc2210093 10.1136/bmj.n1943 10.1056/NEJMc2213948 10.1038/s41467-023-35815-7 10.1101/2022.07.25.22277996 10.1056/NEJMoa2119451 10.1056/NEJMoa2208343 10.1001/jamanetworkopen.2022.32760
ContentType	Journal Article
Copyright	Crown 2023 last corrected publication 2024 2023. Crown. Copyright Nature Publishing Group 2023 Crown 2023
Copyright_xml	– notice: Crown 2023 last corrected publication 2024 – notice: 2023. Crown. – notice: Copyright Nature Publishing Group 2023 – notice: Crown 2023
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7X7 7XB 88E 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P5Z P62 P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 SOI 7X8 5PM DOA
DOI	10.1038/s41467-023-36566-1
DatabaseName	SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Coronavirus Research Database ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Biological Science Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts Environment Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) AIDS and Cancer Research Abstracts ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Immunology Abstracts Environment Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE CrossRef Publicly Available Content Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2041-1723
EndPage	10
ExternalDocumentID	oai_doaj_org_article_0726cc1ced4a494cbcd87728f130eb87 PMC9990563 36882416 10_1038_s41467_023_36566_1
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Ontario Ontario Canada Canada
GeographicLocations_xml	– name: Ontario – name: Ontario Canada – name: Canada
GrantInformation_xml	– fundername: Canadian Immunization Research Network (CNF 151944) – fundername: ;
GroupedDBID	--- 0R~ 39C 3V. 53G 5VS 70F 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ AAHBH AAJSJ ABUWG ACGFO ACGFS ACIWK ACMJI ACPRK ACSMW ADBBV ADFRT ADMLS ADRAZ AENEX AEUYN AFKRA AFRAH AHMBA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH AOIJS ARAPS ASPBG AVWKF AZFZN BBNVY BCNDV BENPR BGLVJ BHPHI BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EE. EMOBN F5P FEDTE FYUFA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ KQ8 LK8 M1P M48 M7P M~E NAO O9- OK1 P2P P62 PIMPY PQQKQ PROAC PSQYO RNS RNT RNTTT RPM SNYQT SV3 TSG UKHRP AASML AAYXX AFFHD CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7QL 7QP 7QR 7SN 7SS 7ST 7T5 7T7 7TM 7TO 7XB 8FD 8FK AZQEC C1K COVID DWQXO FR3 GNUQQ H94 K9. P64 PKEHL PQEST PQUKI PRINS RC3 SOI 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c606t-6a44c822f51606bc26f51eb3669669756e1e8ef2ea753d8330ae9f6ed78af7b73
IEDL.DBID	M7P
ISICitedReferencesCount	35
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000957599200011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2041-1723
IngestDate	Mon Nov 10 04:24:04 EST 2025 Tue Nov 04 02:06:47 EST 2025 Wed Oct 01 12:15:05 EDT 2025 Tue Oct 07 07:16:38 EDT 2025 Mon Jul 21 05:59:48 EDT 2025 Sat Nov 29 02:11:42 EST 2025 Tue Nov 18 22:28:00 EST 2025 Fri Feb 21 02:35:51 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	2023. Crown. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c606t-6a44c822f51606bc26f51eb3669669756e1e8ef2ea753d8330ae9f6ed78af7b73
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-7820-2046 0000-0002-3666-7005 0000-0002-5548-3228 0000-0002-9793-113X 0000-0002-1922-2442
OpenAccessLink	https://www.proquest.com/docview/2784121707?pq-origsite=%requestingapplication%
PMID	36882416
PQID	2784121707
PQPubID	546298
PageCount	10
ParticipantIDs	doaj_primary_oai_doaj_org_article_0726cc1ced4a494cbcd87728f130eb87 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9990563 proquest_miscellaneous_2784835632 proquest_journals_2784121707 pubmed_primary_36882416 crossref_primary_10_1038_s41467_023_36566_1 crossref_citationtrail_10_1038_s41467_023_36566_1 springer_journals_10_1038_s41467_023_36566_1
PublicationCentury	2000
PublicationDate	2023-03-07
PublicationDateYYYYMMDD	2023-03-07
PublicationDate_xml	– month: 03 year: 2023 text: 2023-03-07 day: 07
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature communications
PublicationTitleAbbrev	Nat Commun
PublicationTitleAlternate	Nat Commun
PublicationYear	2023
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	36566_CR14 36566_CR3 36566_CR1 36566_CR8 36566_CR9 R Grewal (36566_CR6) 2022; 378 36566_CR7 D Surie (36566_CR18) 2022; 71 36566_CR4 SA Buchan (36566_CR24) 2022; 5 36566_CR5 H Chung (36566_CR23) 2021; 374 R Link-Gelles (36566_CR10) 2022; 71 36566_CR29 36566_CR28 36566_CR27 36566_CR26 36566_CR25 36566_CR22 36566_CR21 36566_CR20 S Gazit (36566_CR11) 2022; 377 N Andrews (36566_CR2) 2022; 386 S Chalkias (36566_CR19) 2022; 387 S Collie (36566_CR15) 2022; 387 YM Bar-On (36566_CR13) 2022; 386 36566_CR17 36566_CR16 O Magen (36566_CR12) 2022; 386 39706844 - Nat Commun. 2024 Dec 20;15(1):10709. doi: 10.1038/s41467-024-55350-3 37041147 - Nat Commun. 2023 Apr 11;14(1):2031. doi: 10.1038/s41467-023-37906-x
References_xml	– volume: 378 start-page: e071502 year: 2022 ident: 36566_CR6 publication-title: BMJ doi: 10.1136/bmj-2022-071502 – volume: 71 start-page: 931 year: 2022 ident: 36566_CR10 publication-title: MMWR – ident: 36566_CR21 doi: 10.1056/NEJMc2213907 – ident: 36566_CR26 – volume: 386 start-page: 1603 year: 2022 ident: 36566_CR12 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2201688 – volume: 386 start-page: 1712 year: 2022 ident: 36566_CR13 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2201570 – volume: 377 start-page: e071113 year: 2022 ident: 36566_CR11 publication-title: BMJ doi: 10.1136/bmj-2022-071113 – ident: 36566_CR14 – ident: 36566_CR7 – volume: 387 start-page: 1332 year: 2022 ident: 36566_CR15 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2210093 – ident: 36566_CR9 – ident: 36566_CR5 – ident: 36566_CR3 – volume: 374 start-page: n1943 year: 2021 ident: 36566_CR23 publication-title: BMJ doi: 10.1136/bmj.n1943 – ident: 36566_CR28 – ident: 36566_CR20 doi: 10.1056/NEJMc2213948 – ident: 36566_CR22 – ident: 36566_CR17 doi: 10.1038/s41467-023-35815-7 – ident: 36566_CR25 – ident: 36566_CR16 doi: 10.1101/2022.07.25.22277996 – ident: 36566_CR27 – volume: 386 start-page: 1532 year: 2022 ident: 36566_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2119451 – ident: 36566_CR1 – volume: 71 start-page: 1327 year: 2022 ident: 36566_CR18 publication-title: MMWR – volume: 387 start-page: 1279 year: 2022 ident: 36566_CR19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2208343 – ident: 36566_CR8 – ident: 36566_CR4 – volume: 5 start-page: e2232760 year: 2022 ident: 36566_CR24 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2022.32760 – ident: 36566_CR29 – reference: 37041147 - Nat Commun. 2023 Apr 11;14(1):2031. doi: 10.1038/s41467-023-37906-x – reference: 39706844 - Nat Commun. 2024 Dec 20;15(1):10709. doi: 10.1038/s41467-024-55350-3
SSID	ssj0000391844
Score	2.565146
Snippet	We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in Ontario,... Abstract We estimated the effectiveness of booster doses of monovalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults in...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1273
SubjectTerms	631/326/590 631/326/596/4130 692/700/459/1748 692/700/478/174 Adult Adults Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Effectiveness Humanities and Social Sciences Humans Immunization Immunization, Secondary mRNA multidisciplinary Ontario - epidemiology RNA, Messenger SARS-CoV-2 Science Science (multidisciplinary) Severe acute respiratory syndrome coronavirus 2 Vaccine efficacy Vaccines
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqikpcENACgYJciRtYTWKvH8dSqOhlW6EW9WY59gRWogna7Fbi3zO2s0uX54VbEjuSM5nHN5oXIS8nTWW8qz2DVnEmtGiYKSeAyhCkdpqHttFp2ISaTvXVlTm_Neor5oTl9sCZcIelqqX3lYcgnDDCNz5oRIS6ReULjU515KUyt5yppIO5QddFjFUyJdeHg0g6AU0U4xHDsGrDEqWG_b9Dmb8mS_4UMU2G6OQ-uTciSHqUT_6AbEH3kOzkmZLfdslF7kc8KjHat_T6w_SIHp99PH3LKkNvnI-xdIroOvZIoKEfYKDuk5shUKRn1zFBr6NoL2EOtF8ukCNh2COXJ-8ujt-zcXQC8-iRLJh0Qni0_e2kwvvG1xKv0G-WEt0boyYSKtDQ1uDQXQma89KBaSUEpV2rGsUfke2u7-AJoS5Wm2snYpGtUDpoz4OXCPtcE5CmdUGqFRmtH_uKx_EWX2yKb3NtM-ktkt4m0tuqIK_W73zNXTX-uvtN_DvrnbEjdnqAfGJHPrH_4pOC7K_-rR3FdLAp6opOWYnLB-tlFLAYNXEd9Mu8B2Gq5PiljzMrrE_CJTooCGkLojaYZOOomyvd7HNq4o3AHLEnL8jrFTv9ONafSfH0f5DiGblbRzmImXRqn2wv5kt4Tu74m8VsmL9IgvQdr9Ueow priority: 102 providerName: Directory of Open Access Journals
Title	Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
URI	https://link.springer.com/article/10.1038/s41467-023-36566-1 https://www.ncbi.nlm.nih.gov/pubmed/36882416 https://www.proquest.com/docview/2784121707 https://www.proquest.com/docview/2784835632 https://pubmed.ncbi.nlm.nih.gov/PMC9990563 https://doaj.org/article/0726cc1ced4a494cbcd87728f130eb87
Volume	14
WOSCitedRecordID	wos000957599200011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: DOA dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: P5Z dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: M7P dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: 7X7 dateStart: 20100101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: BENPR dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2041-1723 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000391844 issn: 2041-1723 databaseCode: PIMPY dateStart: 20100101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiQuvAuBsjISN4iaxI7tnFBbWtED26gqaOESObZTVqJJ2exW4t8zdrxbLY9euERJ7Eh2xjPzjWc8A_A6r9NCq0zHthE0ZpLVcZHkFoWh5VJJappa-mITYjyWk0lRhg23PoRVLmWiF9Sm026PfNc7yBA_J-Ld5Y_YVY1y3tVQQmMDtlyWhMyH7pWrPRaX_VwyFs7KJFTu9sxLBlRUMXVIJk7X9JFP2_83rPlnyORvflOvjo7u_-9EHsC9AETJ3rByHsIt2z6CO0Npyp-P4WxIaxxkIekacnE63iMHJ5-P38dpQa6Udi55giDdpVogputtT9S5miLeJCcXLs6vJah27cySbjHHsdn-CXw6Ojw7-BCHCgyxRsNmHnPFmEYI0eQpPtc643iH5jfnaCUVIuc2tdI2mVVo9RhJaaJs0XBrhFSNqAXdhs22a-0zIModWpeKubO6TEgjNTWaI3pUtUGiZBGkSzpUOqQnd1UyvlfeTU5lNdCuQtpVnnZVGsGb1TeXQ3KOG3vvO_KuerrE2v5FNzuvAp9Wici41qm2hilWMF1rI9EAkQ3qeltLEcHOkqpV4Pa-uiZpBK9WzcinzvmiWtsthj6IdjnFmT4d1tJqJJSjnYPIOAKxtsrWhrre0k6_-VzgiO8RwtII3i7X4_Ww_v0rnt88ixdwN3Ms4kLtxA5szmcL-xJu66v5tJ-NYENMhL_KEWztH47L05Hfyhh57sNrmX_FlvL4Y_nlFwLKMz4
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHWi8cB8EBhgJniBaE7u284DQ2JhWbesqVKbxZBzHGZVYMpp2aH-K38ixk3Qql73tgbckdiLb-Xz8HftcAF720igxOjahzQUNmWRpmHR7FoWh5VJLmuWp9MkmxGAgj46S4RL8bH1hnFllKxO9oM5K4_bI1_0BGfLnrnh3-j10WaPc6WqbQqOGxa49_4EqW_W2v4X_91Ucb38Ybe6ETVaB0CBZn4ZcM2ZwWcx7Ed6nJuZ4hSol58j8E9HjNrLS5rHVyOQzifq-tknObSakzkUqKH73GiwzB_YOLA_7-8PP810dF29dMtZ453SpXK-Yl0W4NIbUcacwWlgBfaKAv7HbP400fzup9Qvg9u3_bejuwK2GapONem7chSVb3IMbdfLN8_swqgM3N9KelDk5-TjYIJsHh_2tMErImTbO6ICgGuKCSZCsrGxF9LEeI6MmByfOkrEgSCzsxJJyNsWxsNUD-HQlXVqFTlEW9hEQ7dzypWbOG5kJmUlDM8ORH-s0QxDEAUTtf1emCcDu8oB8U94QgEpVY0UhVpTHiooCeD1_57QOP3Jp7fcOTvOaLnS4f1BOjlUjiVRXxNyYyNiMaZYwk5pMooolc2QzNpUigLUWRaqRZ5W6gFAAL-bFKInc8ZIubDmr6yCf5xR7-rDG7rwllKMmh9w_ALGA6oWmLpYU468-2jlqMEjSaQBvWvxfNOvfQ_H48l48h5Wd0f6e2usPdp_AzdhNT2dYKNagM53M7FO4bs6m42ryrJnhBL5c9cz4Bcsqih8
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4a4yJeuDMCA4wET2C1SVzbeUBorFRUQ12FBpp4MY7jbJVYMpp2aH-NX8exc5nKZW974K1p3Mp2vnP8ffHxOQDPB2mYGB0ZanMRUyZZSpP-wKIztFxqGWd5Kn2xCTGZyP39ZLoGP9uzMC6ssvWJ3lFnpXHvyHt-gwz5c1_08iYsYjocvTn-Tl0FKbfT2pbTqCGyY09_oHyrXo-H-KxfRNHo3d72e9pUGKAGifuCcs2YwSUyH4R4nZqI4yeUl5yjCkjEgNvQSptHViOrzyRqf22TnNtMSJ2LVMT4v5fgskCN6cIJp4Mv3fsdl3ldMtac0-nHslcx75VwkaSxY1E0XFkLfcmAv_HcP8M1f9uz9Uvh6Ob_PIm34EZDwMlWbTG3Yc0Wd-BqXZLz9C7s1emcmzWAlDk5-jjZItu7n8dDGibkRBsXikBQnLgUEyQrK1sRfaBnyLPJ7pGLbywI0g07t6RcLnBebHUPPl3IkO7DelEW9gEQ7Q7rS83cGWUmZCZNnBmOrFmnGQIiCiBsMaBMk5bdVQf5pnx4QCxVjRuFuFEeNyoM4GX3m-M6Kcm5rd86aHUtXUJx_0U5P1CNf1J9EXFjQmMzplnCTGoyicJL5shxbCpFAJstolTj5Sp1BqcAnnW30T-5TSdd2HJZt0GWz2Mc6UaN464nMUd9h4ogALGC8JWurt4pZoc-BzrqGqTucQCvWls469a_p-Lh-aN4CtfQHNSH8WTnEVyPnKW6aEOxCeuL-dI-hivmZDGr5k-8qRP4etFm8QszOJGC
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+mRNA+COVID-19+vaccine+booster+doses+against+Omicron+severe+outcomes&rft.jtitle=Nature+communications&rft.au=Grewal%2C+Ramandip&rft.au=Nguyen%2C+Lena&rft.au=Buchan%2C+Sarah+A.&rft.au=Wilson%2C+Sarah+E.&rft.date=2023-03-07&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41467-023-36566-1&rft.externalDocID=10_1038_s41467_023_36566_1
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon